| Authors found that the phenotypic alterations by miR-365 were partially due to downregulation of CCND1 and BCL2 oncogenes. | None |
| Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. | None |
| Cyclin D1 as a cellular proto-oncogene. | None |
| PRAD1/cyclin D1 proto-oncogene: genomic organization, 5 DNA sequence, and sequence of a tumor-specific rearrangement breakpoint. | None |
| Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. | None |
| Cyclin D1 as the putative bcl-1 oncogene. | None |
| Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. | None |
| Coding sequence of the overexpressed transcript of the putative oncogene PRAD1/cyclin D1 in two primary human tumors. | None |
| Two potentially oncogenic cyclins, cyclin A and cyclin D1, share common properties of subunit configuration, tyrosine phosphorylation and physical association with the Rb protein. | None |
| The cyclin D1/PRAD1 oncogene in human neoplasia. | None |
| Overexpression of the PRAD1 oncogene in a patient with multiple myeloma and t(11;14)(q13;q32). | None |
| Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras oncogene in neoplastic transformation. | None |
| A novel triplex-forming oligonucleotide targeted to human cyclin D1 (bcl-1, proto-oncogene) promoter inhibits transcription in HeLa cells. | None |